T-cell assays confirm immunogenicity of tungsten-induced erythropoietin aggregates associated with pure red cell aplasia

Blood Advances

Volumn 1, Issue 6, 2017, Pages 367-379

  Rubic Schneider, Tina ^a   Kuwana, Masataka ^b,e   Christen, Brigitte ^a   Aßenmacher, Manuela ^c   Hainzl, Otmar ^c   Zimmermann, Frank ^c   Fischer, Robert ^c   Koppenburg, Vera ^d   Chibout, Salah Dine ^a   Wright, Timothy M ^a,f   Seidl, Andreas ^c   Kammüller, Michael ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Novartis Biologics Technical Development and Manufacturing   (Germany)

^d Sandoz Biopharmaceuticals   (Germany)

^e NIPPON MEDICAL SCHOOL   (Japan)

^f REGULUS THERAPEUTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85034005405     PISSN: 24739529     EISSN: 24739537     Source Type: Journal    
DOI: 10.1182/bloodadvances.2016001842     Document Type: Article

References (34)

1. Parenky A, Myler H, Amaravadi L, et al. New FDA draft guidance on immunogenicity. AAPS J. 2014;16(3):499-503.
2. Tatarewicz SM, Mytych DT, Manning MS, Swanson SJ, Moxness MS, Chirmule N. Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact. Bioanalysis. 2014;6(11):1509-1523.
3. Wang W, Singh SK, Li N, Toler MR, King KR, Nema S. Immunogenicity of protein aggregates–concerns and realities. Int J Pharm. 2012;431(1-2):1-11.
4. Ratanji KD, Derrick JP, Dearman RJ, Kimber I. Immunogenicity of therapeutic proteins: influence of aggregation. J Immunotoxicol. 2014;11(2):99-109.
5. Joubert MK, Hokom M, Eakin C, et al. Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem. 2012;287(30):25266-25279.
6. Rombach-Riegraf V, Karle AC, Wolf B, et al. Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro [published correction appears in PLoS One. 2014;9(3):e93339]. PLoS One. 2014;9(1):e86322.
7. Jawa V, Cousens LP, Awwad M, Wakshull E, Kropshofer H, De Groot AS. T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation. Clin Immunol. 2013;149(3):534-555.
8. Ahmadi M, Bryson CJ, Cloake EA, et al. Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics. Pharm Res. 2015;32(4):1383-1394.
9. Joubert MK, Deshpande M, Yang J, et al. Use of in vitro assays to assess immunogenicity risk of antibody-based biotherapeutics. PLoS One. 2016;11(8): e0159328.
10. Means RT Jr. Pure red cell aplasia. Blood. 2016;128(21):2504-2509.
11. Macdougall IC, Roger SD, de Francisco A, et al. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesisstimulating agents: new insights. Kidney Int. 2012;81(8):727-732.
12. Haag-Weber M, Eckardt KU, Hörl WH, Roger SD, Vetter A, Roth K. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-a (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clin Nephrol. 2012;77(1):8-17.
13. Seidl A, Hainzl O, Richter M, et al. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res. 2012;29(6):1454-1467.
14. Barger TE, Wrona D, Goletz TJ, Mytych DT. A detailed examination of the antibody prevalence and characteristics of anti-ESA antibodies. Nephrol Dial Transplant. 2012;27(10):3892-3899.
15. Weeraratne DK, Kuck AJ, Chirmule N, Mytych DT. Measurement of anti-erythropoiesis-stimulating agent IgG4 antibody as an indicator of antibody-mediated pure red cell aplasia. Clin Vaccine Immunol. 2013;20(1):46-51.
16. Crotty S. A brief history of T cell help to B cells. Nat Rev Immunol. 2015;15(3):185-189.
17. Saade F, Gorski SA, Petrovsky N. Pushing the frontiers of T-cell vaccines: accurate measurement of human T-cell responses. Expert Rev Vaccines. 2012; 11(12):1459-1470.
18. Britten CM, Janetzki S, Butterfield LH, et al. T cell assays and MIATA: the essential minimum for maximum impact. Immunity. 2012;37(1):1-2.
19. Tangri S, Mothé BR, Eisenbraun J, et al. Rationally engineered therapeutic proteins with reduced immunogenicity. J Immunol. 2005;174(6):3187-3196.
20. Kuwana M, Medsger TA Jr, Wright TM. T cell proliferative response induced by DNA topoisomerase I in patients with systemic sclerosis and healthy donors. J Clin Invest. 1995;96(1):586-596.
21. Swanson SJ, Ferbas J, Mayeux P, Casadevall N. Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin Pract. 2004;96(3):c88-c95.
22. Martinuzzi E, Afonso G, Gagnerault MC, et al. acDCs enhance human antigen-specific T-cell responses. Blood. 2011;118(8):2128-2137.
23. Cravedi P, Manrique J, Hanlon KE, et al. Immunosuppressive effects of erythropoietin on human alloreactive T cells. J Am Soc Nephrol. 2014;25(9): 2003-2015.
24. Abulafia-Lapid R, Elias D, Raz I, Keren-Zur Y, Atlan H, Cohen IR. T cell proliferative responses of type 1 diabetes patients and healthy individuals to human hsp60 and its peptides. J Autoimmun. 1999;12(2):121-129.
25. Roep BO, Atkinson MA, van Endert PM, Gottlieb PA, Wilson SB, Sachs JA. Autoreactive T cell responses in insulin-dependent (Type 1) diabetes mellitus. Report of the first international workshop for standardization of T cell assays. J Autoimmun. 1999;13(2):267-282.
26. Faulkner L, Meng X, Naisbitt DJ, Spraggs CF, Park BK. No evidence for drug-specific activation of circulating T cells from patients with HLA-DRB1*07: 01-restricted lapatinib-induced liver injury. Chem Res Toxicol. 2016;29(12):2111-2113.
27. Mallone R, Mannering SI, Brooks-Worrell BM, et al; T-Cell Workshop Committee, Immunology of Diabetes Society. Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. Clin Exp Immunol. 2011;163(1):33-49.
28. Attaf M, Huseby E, Sewell AK. ab T cell receptors as predictors of health and disease. Cell Mol Immunol. 2015;12(4):391-399.
29. Praditpornsilpa K, Kupatawintu P, Mongkonsritagoon W, et al. The association of anti-r-HuEpo-associated pure red cell aplasia with HLA-DRB1*09-DQB1*0309. Nephrol Dial Transplant. 2009;24(5):1545-1549.
30. Fijal B, Ricci D, Vercammen E, et al. Case-control study of the association between select HLA genes and anti-erythropoietin antibody-positive pure red-cell aplasia. Pharmacogenomics. 2008;9(2):157-167.
31. Osterburg AR, Robinson CT, Schwemberger S, Mokashi V, Stockelman M, Babcock GF. Sodium tungstate (Na2WO4) exposure increases apoptosis in human peripheral blood lymphocytes. J Immunotoxicol. 2010;7(3):174-182.
32. Jiang Y, Nashed-Samuel Y, Li C, et al. Tungsten-induced protein aggregation: solution behavior. J Pharm Sci. 2009;98(12):4695-4710.
33. Delluc S, Ravot G, Maillere B. Quantification of the preexisting CD4 T-cell repertoire specific for human erythropoietin reveals its immunogenicity potential. Blood. 2010;116(22):4542-4545.
34. Broxmeyer HE. Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration. J Exp Med. 2013;210(2): 205-208.